Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

NCLT approves the scheme of amalgamation of Lincoln Parenteral Ltd and Lincoln Pharmaceuticals Ltd

Posted On: 2021-09-16 13:14:52 (Time Zone: IST)


Hon'ble National Company Law Tribunal, Ahmedabad Bench, (NCLT) has approved the scheme of amalgamation of Lincoln Parenteral Ltd and Lincoln Pharmaceuticals Ltd under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. Amalgamation is expected to bring lot of synergies in terms of operations efficiency, enhance competitive strength, cost-effectiveness and productivity for the combined entity.

The order sanctioning the scheme was pronounced on September 14, 2021 and uploaded on the website of Hon'ble NCLT on September 15, 2021. Appointed date of the scheme is April 01, 2019. The scheme will be effective upon filing of certified copy of the order of the Hon'ble NCLT with the Registrar of Companies, Gujarat.

Lincoln Parenteral Ltd is subsidiary company of Lincoln Pharmaceuticals Ltd engaged in the business of small Parenteral Injection Products. For the year ended March 2021, Lincoln Parenteral reported turnover of Rs. 44.64 crore and Net profit of Rs. 1.84 crore. Lincoln Pharmaceuticals Ltd holds 98.58% in Lincoln Parenteral Ltd as on March 2021.

During FY20-21, Lincoln Pharmaceuticals Ltd had filled petition with Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench for approve of the scheme of amalgamation of Lincoln Parenteral Limited ("Transferor Company") with Lincoln Pharmaceuticals Limited ("Transferee Company") and their respective Shareholders and Creditors.

Commenting on the development, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "The corporate restructuring practice will bring lot of synergies for the both the company and will lead to increased competitive strength, cost reduction and efficiencies, productivity gains, and logistic advantages, thereby significantly contributing to future growth. We are confident to improve our growth numbers of revenue, margins and profitability in FY22. Our strategic growth initiatives, product and geographical expansion, operational efficiency and debt free status are likely to maximise value for all stakeholders in the near to medium term."

Shares of Lincoln Pharmaceuticals ltd. was last trading in BSE at Rs. 393.7 as compared to the previous close of Rs. 383.55. The total number of shares traded during the day was 21256 in over 1154 trades.

The stock hit an intraday high of Rs. 396.6 and intraday low of 379.1. The net turnover during the day was Rs. 8241306.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

TVS Motor Company wins India Green Energy Award

Zuari Agro Chemicals Limited announces shutdown of NPK plants

Metropolis Healthcare completes acquisition of chain of labs in South India called 'Hitech Diagnostic Centre'

Ravi Kumar Distilleries Ltd resumes operations at factory

JK Cement Ltd and PRESPL sign a Strategic MoU to Curate a 'Decarbonisation Path', envisioned for Decade and Beyond

Bank of India opens first ever branch in Leh

Kotak Partners Pine Labs as it scales up its Merchant Acquiring Business

IndiGo transported 67.9% of the vaccines as India touches 100-crore dose milestone

Cybertech Systems and Software Ltd Q2FY22 consolidated PAT at Rs. 8.47 crore

Reliance Industries Ltd Q2FY22 consolidated PAT rises to Rs. 13680 crore

Dodla Dairy Ltd Q2FY22 consolidated net profit drops to Rs. 29.39 crore

Zenotech Laboratories Ltd posts Rs. 94.64 lakhs profit in Q2FY22

Inventure Growth and Securities Ltd Q2FY22 consolidated PAT at Rs. 3.70 crore

The Federal Bank Ltd reports consolidated PAT of Rs. 487.99 crore in Q2FY22

Crompton Greaves Consumer Electricals Ltd Q2FY22 consolidated PAT up at Rs. 158.81 crore

Tata Consumer Products Ltd consolidated Q2FY22 PAT at Rs. 268.04 crores

Pioneer Distilleries Ltd Q2FY22 loss at Rs. 21.79 crore

Tata Elxsi Ltd Q2FY22 net profit rises to Rs. 125.33 crore

Kirloskar Ferrous Industries Ltd posts Rs. 119.91 crores PAT in Q2FY22

Control Print Ltd posts Rs. 9.83 crore consolidated PAT in Q2FY22

Sacheta Metals Ltd Q2FY22 net profit at Rs. 0.42 crore

TCI Developers Ltd reports consolidated PAT at Rs. 14.35 lakhs

Huhtamaki India Ltd reports Q3CY21 loss at Rs. 21.84 crore

Garment Mantra Lifestyle Ltd opens 13th store at Surat, Gujarat

Globalspace Technologies Ltd Board recommends Final Dividend of Rs. 0.20

Prismx Global Ventures Ltd launches 'Gudgudi' The First OTT Channel

2021 TCS New York City Marathon App Lets Fans Enjoy a Hybrid Race Experience

Kranti Industries Ltd receives in-principle approval for migration to main board

B P Capital Ltd allots 30 lakh warrants

NALCO's Lean Slurry Project at Angul

Trimurthi Ltd acquires property in Hyderabad

Wendt India Ltd reports earnings for Q2FY22

Shanthi Gears Limited Q2 Revenue at Rs. 71.8 Crs and PBT Rs. 11.3 Crs

TCS & Shell Recognized with 2021 ISG Digital Case Study Award™ for Digital Transformation

Siemens Limited to procure solar power for Kalwa facility

Surana Solar Ltd invests in Surana Infotech Pvt Ltd

PVR announces results for the Quarter & Half Year ended September 30, 2021

Ramkrishna Forgings Ltd Opens Offices in Russia & Europe to further expand its global footprints

INOX Leisure Ltd - Q2'FY22 Financial Results Highlights

Steel Strips Wheels Ltd fixes Nov 22, 2021 as record date for stock split

Apollo Pipes Ltd Board recommends 2:1 Bonus Issue

TCI Express Ltd Board approves interim dividend of Rs. 3

Supreme Industries Ltd Board declares Interim Dividend of Rs. 6

Kajaria Ceramics Ltd Board declares Interim Dividend of Rs. 8

J. Kumar Infraprojects Ltd JV bags order worth Rs. 205.49 crore

Lupin life signs Hrlthik Roshan as the brand ambassador for Be One, Ayurvedic Energy Supplement

Welspun Corp Signs MoU With BP India Pvt. Ltd.

Adani Renewable Energy Holding Fifteen Ltd receives LOA from SECI for 450MW wind power project

The Indian Hume Pipe Company Limited receives LoA for Rs. 156.27 crores order

Zydus announces 'first patient' randomised in EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in NASH


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020